The renewed interest in therapeutic targeting of the innate immune response is in accord with the existing data supporting the pathogenic role of the activation of the DDR pathways, particularly the CDSP pathway as well as the salubrious effects of the blockade of the DDR pathways in cardiovascular disease. This evidence concerns the gene SLC22A5 and cardiovascular disorder.